Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Inclusion Criteria: * Any autologous or syngeneic patient who underwent high dose melphalan (\>= 140 mg/m\^2) therapy/peripheral blood stem cell (PBSC) or bone marrow (BM) rescue for any stage of multiple myeloma and did not participate in another clinical transplant trial which is also evaluating long-term disease free survival or survival * Platelet count (transfusion independent) \> 50,000 cells/mm\^3 and absolute granulocyte count \> 1500 cells/mm\^3 for 5 calendar days after recovery from high dose therapy * Patients should be between 30 days to 120 days after transplant * Willingness and ability to comply with Food and Drug Administration (FDA)-mandated REV ASSIST Program, Celgene System for Lenalidomide Education and Prescribing Safety * Signing a written informed consent form Exclusion Criteria: * Karnofsky score less than 70 * A left ventricular ejection fraction less than 45% immediately pre transplant; patients with congestive heart disease with transplant, history of myocardial infarction (MI), or history of coronary artery disease * Total bilirubin greater than 2 mg/ml (unless history of Gilbert's disease), serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) \> 2.5 x upper limit of normal * Calculated by Cockcroft-Gault formula or measured serum creatinine clearance \< 25 ml/minute * Pregnant and/or lactating females * Patients who cannot give informed consent * Patients with untreated systemic infection * Patients wi…